(Q39491356)

English

An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21836633%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21836633%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

oncolytic virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pancreatic cancer

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21836633%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Madhumita Bhattacharyya

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21836633%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

J Francis

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21836633%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

A Eddouadi

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21836633%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

G Halldén

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21836633%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

publication date

12 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21836633%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Cancer Gene Therapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21836633%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21836633%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21836633%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

734-743

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21836633%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

https://scigraph.springernature.com/pub.10.1038/cgt.2011.45

0 references

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Recent progress in the battle between oncolytic viruses and tumours

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Oncolytic viral therapies - the clinical experience

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Adenovirus overrides cellular checkpoints for protein translation

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

China approves world's first oncolytic virus therapy for cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

A double missense variation of the BUB1 gene and a defective mitotic spindle checkpoint in the pancreatic cancer cell line Hs766T.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Restricted replication of human adenovirus type 5 in mouse cell lines

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Adenovirus-5 E1A: paradox and paradigm

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Adenovirus E1A oncogene expression in tumor cells enhances killing by TNF-related apoptosis-inducing ligand (TRAIL).

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

p53-independent apoptosis induced by paclitaxel through an indirect mechanism

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

E1A as a tumor suppressor gene: commentary re S. Madhusudan et al. A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HE

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

21 January 2018

Chemotherapy for advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

7 January 2021

based on heuristic

inferred from DOI database lookup

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

7 January 2021

based on heuristic

inferred from DOI database lookup

Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.45

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39491356&oldid=1521358668"